1. Medtech Insight
  2. >>Business
  3. >>R&D

Gore Unleashes Tigris Peripheral Stent In The US

 
• By Reed Miller

The company says the device's flexibility and durability give it critical advantages over other stents in difficult-to-treat peripheral arteries.

Tigris
Gore's Tigris stent for the superficial femoral or proximal popliteal arteries • Source: WL Gore

WL Gore & Associates Inc. expects US FDA approval of its Tigris heparin-coated peripheral vascular stent, announced Aug. 2, to expand the peripheral artery disease patient population that can be safely treated with vascular stents.

According to Gore, there are between 8 million and 12 million peripheral artery disease patients in the US. Treating diseased...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

BCI Maker INBRAIN Inks Deal With Microsoft To Explore Agentic AI Use For Monitoring Patients

 
• By Marion Webb

INBRAIN teamed up with Microsoft to apply agentic AI to analyze real-time brain data and eventually recommend programming like a “mini-neurologist,” said CEO Carolina Aguilar. It also seeks to enable scalable deployment of INBRAIN’s graphene-based technology and potential joined research.

Prosthetics: Firms Like Unhindr And Esper Shape Market On the Cusp of Great Change

 
• By Barnaby Pickering

The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 
• By Brian Bossetta

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.

More from Business

Deals Shaping The Medtech And Diagnostics Industries, October 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 
• By Brian Bossetta

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.